DNER and cancer: While broad BET inhibitors (BETi) targeting both the BD1 and BD2 domains have demonstrated efficacy in preclinical and clinical settings, particularly for cancer and inflammatory diseases, they can cause undesirable side effects, owing to the essential roles of BET proteins in normal cellular functions [21,22,23,24].